Glaxosmithkline Pharmaceuticals Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/m4dz32u8owcd7oupteb44dng.pdf

Key Takeaways


Revenue Headwinds: A Flat Quarter Deconstructed

Bhushan Akshikar: "we have not only defended or gained market share for many of our key assets, but we have also grown ahead of the market in terms of evolution index both in general medicines as well as vaccines."

Oncology: The New Growth Platform Goes Live

Bhushan Akshikar: "We go live on Independence Day. So, that is where our commitment in our first year of this second century of operation in India is to recommit ourselves to offer freedom to all those patients who deserve, who are unfortunately suffering from these gynecological malignancies and who can benefit with two innovative assets."

Vaccines & Specialty: The Steady Growth Engine

Bhushan Akshikar: "The adult vaccination ecosystem is an area where we remain committed and putting more energy. So, we are confident of maintaining or growing that growth base from here on."

Augmentin & Antibiotic Stewardship


Margins & Expense Phasing

Juby Chandy: "But that said, as the general medicines portfolio grows, we will be able to maintain that absolute margin and the impact on the margin dilution will take a little bit longer term to see. At least in the next 2-3 years, we will not see a dilution in the margins because the ratio at which that grows, the general medicine, the larger base grows, we will dilute any margin dilution we would see from the above."

Trade Generics & Regulatory Landscape


Guidance & Commitments

CommitmentSpecificsTimeline
Oncology revenue startZejula and Jemperli revenue begins reflecting in financialsQ2 FY26
Derm business recoveryVolume growth expected back in derm portfolioQ2 FY26
NLEM price hike realizationFull benefit of price hikes flows throughQ2 FY26 and beyond
Calpol supply normalizationSupply stabilized from affected CMOJuly-August 2025
Margin dilution protectionNo dilution in margins from innovative product mixAt least next 2-3 years
RSV vaccine launchLaunch in IndiaCalendar year 2026
EBITDA margin maintenanceConfident of holding current margin levelsOngoing

Key Metrics

MetricQ1 FY26
Revenue growthFlat, softer than expected tailwinds in antibiotics and derma portfolio
EBITDA margin31.2%, 290 bps improvement YoY with 9.3% growth
PAT growth12.7% YoY, stepped up 290 bps
EPS₹12.08, 13% growth YoY
Cash conversion100% of sales for the quarter converted to cash
Overall price hike2.83% (including vaccines)
Vaccines value growth8.6% YoY
General medicines value growthNegative 2% YoY
Revenue impact from CMO fire1.7% of sales lost; underlying growth 1.7% excluding this
NLEM portfolio share~40% of portfolio
Shingrix monthly doses~9,000-10,000 doses per month, private self-pay segment
Shingrix annual targetIn excess of 100,000 doses, translating to over ₹100 cr
Oncology sales force~20 key account specialists, targeting ~1,200 medical oncologists and ~500 dermatologists
Omni-channel reach4.6 lakh doctors with consent, up from ~3 lakh before digital acceleration
Sourcing from GSK Nashik facility35%-40%; remaining 60% from CMOs